DJIA 17,761.93 -16.22 -0.09%
NASDAQ 4,742.59 -5.81 -0.12%
S&P 500 2,062.69 1.46 0.07%
market minute promo

Roche Holding Ltd. (ADR) (NASDAQOTH: RHHBY)

34.63 -2.27 (-6.15%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

RHHBY $34.66 -6.08%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $34.77
Previous Close $36.90
Daily Range $34.58 - $34.79
52-Week Range $33.23 - $38.71
Market Cap $194.6B
P/E Ratio 0.00
Dividend (Yield) $0.00 (2.5%)
Volume 805,220
Average Daily Volume 892,668
Current FY EPS $1.95

Sector

Healthcare

Industry

Pharmaceuticals

Roche Holding Ltd. (ADR) (RHHBY) Description

Website:

News & Commentary

3 Beaten Down Stocks Ready to Bounce Back

Not all stocks had a great 2014. Here are three stocks that could be ready for a comeback.

This Growing Concern Accounts For Nearly 500,000 Cancer Cases Each Year

A recent World Health Organization study shows that this growing problem is responsible for nearly a half-million cancer diagnoses each year.

This is Incredibly Good News for Breast Cancer Survivors

A recently released study from Canada shines light on the advancements made in treating breast cancer over the past two decades.

Why Inovio Pharmaceuticals Inc. Stock Plunged 15% in November

Inovio Pharmaceuticals stock dips by double-digits in November after the company witnesses a key licensing deal with a major pharmaceutical company come to an end.

This High-Yield Dividend Stock Screams Danger

This high-yield dividend stock may be paying out north of 7%, but its long-term outlook might have investors wisely running in the opposite direction.

Why Shareholders of Organovo Holdings Inc Have Been Waiting For This Day

This 3D bioprinting company finally has a product on the market.

Why Novartis and Regeneron Care About This Tiny Biotech Stock

Ophthotech's Fovista may tip the scale in favor of either Novartis' Lucentis or Regeneron's Eylea.

3 Drugs That Make Gilead Sciences' Harvoni Look Cheap

Cancer drugs from Bristol-Myers Squibb, Novartis, and Roche come with higher price tags than Gilead Sciences hepatitis C drug Harvoni.

Pharmacyclics, Inc.'s Imbruvica Holds Its Own Against Gilead Sciences, Inc.'s Zydelig

Pharmacyclics third-quarter results showed impressive sales growth for Imbruvica, a drug that competes against Gilead's Zydelig.

Why Exelixis, Inc. Stock Pushed 11% Higher in October

Exelixis was one of the best biotech stocks in October. Find out what sent its shares higher by 11% and whether or not the good times will keep rolling for this small-cap biotech stock.

See More RHHBY News...

RHHBY's Top Competitors

RHHBY $34.63 (-6.15%)
Current stock: RHHBY
JNJ $106.44 (-0.35%)
Current stock: JNJ
NVS $94.17 (-0.42%)
Current stock: NVS
GSK $43.15 (-0.32%)
Current stock: GSK